登录

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

Mailman 2020-01-17 17:52

Bayer
https://www.bayer.com/
企业数据由 动脉橙 提供支持
医药产品研发商 | IPO后其它轮次 | 运营中
德国-北莱茵-威斯特法伦州
2022-11-08
Bill and Melinda Gates Foundation
查看

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany GmbH will take over the operations of one of Bayer's final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.


Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant). The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions. Financial details were not disclosed.


"We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities," said Dr. Chris Chen, CEO of WuXi Biologics. "Our business in the EU, US and China market has experienced robust growth in the past few years. This additional drug product plant further confirms our commitment to 'Global Dual Sourcing within WuXi Biologics' strategy. WuXi Biologics will continue to expand our worldwide capacity, providing global partners with a robust and premier-quality supply chain network to benefit patients worldwide."


WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. 


WuXi Biologics is committed to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in the pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. The company is going to provide its biomanufacturing partners with a robust and premier-quality global supply chain network with a total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022.


Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. 


Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

120多名医生参加了关于介入骨科和非手术治疗进展的会议

Medgate Today 2024-07-13 20:52

北京大学第三医院4个牵头项目荣获2023年北京医学科技奖

北京大学医学部 2024-07-13 20:23

与NeoRAS野生型转移性癌症相关的临床特征——SCRUM-Japan GOZILA亚研究

Nature 2024-07-13 19:13

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

Bayer

医药产品研发商

立即沟通

药明生物

生物制剂研发商

立即沟通
产业链接
查看更多